Clinical Trials
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
Zhao et alThe New England Journal of Medicine

In the phase 3, multicenter, open-label, randomized TAISHAN-302 trial (NCT06612151), researchers evaluated the efficacy and safety of tambotatug pelitecan (Tam-Peli), an antibody-drug conjugate directed against the immune-checkpoint molecule B7-H3, in comparison with standard-of-care topotecan for patients with small-cell lung cancer (SCLC) that had progressed after first-line platinum-based chemotherapy.
A total of 451 eligible patients were randomized in a 1:1 ratio to receive either tambotatug pelitecan (n = 225) or topotecan (n = 226). The primary endpoint was overall survival (OS), and key secondary endpoints included investigator-assessed progression-free survival (PFS) and objective response rate.
At the prespecified interim analysis, tambotatug pelitecan demonstrated statistically significant and clinically meaningful improvements across all major efficacy metrics. Median overall survival was 13.3 months (95% CI, 12.1 to could not be estimated) in the tambotatug pelitecan cohort compared to 9.4 months (95% CI, 7.7 to 10.5) in the topotecan cohort, translating to a 54% reduction in the risk of death (stratified HR, 0.46; 95% CI, 0.35 to 0.62; P < 0.001).
Progression-free survival was also significantly prolonged with tambotatug pelitecan relative to topotecan, with a median of 7.4 months (95% CI, 6.1 to 7.6) versus 2.8 months (95% CI, 1.8 to 3.0), respectively (stratified HR, 0.29; 95% CI, 0.23 to 0.37; P < 0.001). Furthermore, the confirmed objective response rate was 59.1% with the B7-H3 antibody-drug conjugate compared with 9.7% with topotecan (P < 0.001).
In addition to superior efficacy, tambotatug pelitecan was associated with a more favorable toxicity profile. Grade 3 or higher adverse events occurred in 55.4% of patients treated with tambotatug pelitecan compared to 77.9% of patients treated with topotecan. The study was funded by the Innovative Drug Research and Development National Science and Technology Major Project and MediLink Therapeutics.
Key Takeaways
- Tambotatug pelitecan significantly extended median overall survival compared with topotecan (13.3 vs. 9.4 months; HR 0.46, 95% CI 0.35 to 0.62; P < 0.001) in patients with small-cell lung cancer relapsing after platinum-based therapy.
- Treatment with tambotatug pelitecan improved median progression-free survival (7.4 vs. 2.8 months; HR 0.29, 95% CI 0.23 to 0.37; P < 0.001) and markedly raised the confirmed objective response rate (59.1% vs. 9.7%, P < 0.001).
- Tambotatug pelitecan demonstrated a superior safety profile over topotecan, with a lower overall incidence of grade 3 or higher adverse events (55.4% vs. 77.9%).
Read the original sourceThe New England Journal of Medicine
